IRMD - Iradimed Co - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

IRMD is currently covered by 1 analysts with an average price target of $86.59. This is a potential upside of $16.77 (24.02%) from yesterday's end of day stock price of $69.82.

Iradimed Co's activity chart (see below) currently has 0 price targets and 3 ratings on display. The stock rating distribution of IRMD is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 100% with an average time for these price targets to be met of 273 days.

Highest price target for IRMD is $72, Lowest price target is $72, average price target is $72.

Most recent stock forecast was given by JASON WITTES from ROTH MKM on 14-Feb-2025. First documented stock forecast 22-Apr-2024.

Best performing analysts who are covering IRMD - Iradimed Co:

Jason Wittes

Currently out of the existing stock ratings of IRMD, 3 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Jason Wittes (ROTH MKM)

Buy

$72

$1.62 (2.30%)

$60

6 months 6 days ago
(14-Feb-2025)

3/3 (100%)

$16.77 (30.36%)

273

Please subscribe to see the analyst performance score

Show more analysts

Load Price Targets and Ratings Chart

To gain access for the analyst/ stock price target chart please use a computer

What is IRMD (Iradimed Co) average time for price targets to be met?

On average it took 273 days on average for the stock forecasts to be realized with a an average price target met ratio 100

Which analyst has the current highest performing score on IRMD (Iradimed Co) with a proven track record?

JASON WITTES

Which analyst has the most public recommendations on IRMD (Iradimed Co)?

Jason Wittes has 9 price targets and 8 ratings on IRMD

Which analyst is the currently most bullish on IRMD (Iradimed Co)?

Jason Wittes with highest potential upside - $1.62

Iradimed Co in the News

Iradimed outlines $100M revenue run-rate for 2026 driven by new 3870 pump launch

Earnings Call Insights: IRADIMED CORPORATION (IRMD) Q2 2025 MANAGEMENT VIEW * Roger E. Susi, CEO, reported “yet another record quarter, marking our 16th consecutive quarter of record revenues.” He highlighted Q2 2025 revenue of $20.4 million, a 14% increase over the prior year, and noted gross profit at 78% and an 18% rise in GAAP...

IRADIMED CORP (NASDAQ:IRMD) Reports Record Q2 2025 Earnings, Raises Full-Year Guidance Amid Strong Market Rally

IRADIMED CORP (NASDAQ:IRMD [https://www.chartmill.com/stock/quote/IRMD]) reported its second-quarter 2025 financial results, delivering record revenue and earnings that exceeded analyst expectations. The company also raised its full-year guidance, signaling confidence in its growth trajectory. Here’s a breakdown of the key takeaways from the earnings release and how the market has responded so far. EARNINGS AND REVENUE PERFORMANCE...